Pliant Therapeutics (PLRX) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and leadership

• Focused on developing novel integrin-based small molecule therapeutics for fibrotic diseases, with a lead program in bexotograst targeting idiopathic and progressive pulmonary fibrosis and primary sclerosing cholangitis.

• Pipeline includes oncology, muscular dystrophy, and other fibrosis-related programs, all leveraging a proprietary integrin-targeting platform.

• Leadership team brings extensive experience in pharma, biotech, and investment banking.

Market landscape and strategy

• Interstitial lung diseases (ILDs) represent a diverse group, with IPF making up about 60% of cases; combined ILD market projected to grow from $4B to $10-11B by 2034.

• Estimated 500,000 ILD patients across major markets, with incidence expected to rise.

• Bexotograst targets key integrins upregulated in various fibrotic lung diseases, supporting expansion beyond IPF.

• Plans to accelerate development in progressive pulmonary fibrosis, potentially launching umbrella studies to capture broader patient populations.

Clinical data and competitive positioning

• Bexotograst has shown potent anti-fibrotic effects across multiple forms of lung fibrosis, with positive data in scleroderma and RA models.

• INTEGRIS-IPF phase 2b/3 study demonstrates strong safety, low diarrhea rates, and statistically significant improvements in FVC, especially at higher doses.

• Collagen PET and biomarker studies confirm reduction in lung collagen and favorable changes in predictive biomarkers like integrin beta-6.

• Recent competitor success in phase 3 (Boehringer) validates the translatability of phase 2 data and supports confidence in upcoming readouts.